Allakos INC

Allakos Inc. finalizes its merger with Concentra Biosciences, resulting in the company becoming a wholly-owned subsidiary and delisting from the Nasdaq Global Select Market.

Allakos Inc. has entered into a definitive agreement to be acquired by Concentra Biosciences, LLC for $0.33 per share in cash.

Allakos Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

Allakos reports Q4 2024 financial results, provides a business update including discontinuing AK006 development, restructuring operations, and exploring strategic alternatives.

Allakos Inc. will discontinue development of AK006, reduce its workforce by 75%, and explore strategic alternatives after a Phase 1 study in Chronic Spontaneous Urticaria (CSU).

Allakos Inc. announced the discontinuation of its AK006 program after disappointing clinical trial results, leading to a significant workforce reduction and exploration of strategic alternatives.

Allakos Inc. reports Q1 2025 results, highlighted by a merger agreement with Concentra Biosciences following the discontinuation of AK006 development and a strategic review.

Allakos Inc. announced its third quarter 2024 financial results, highlighting progress in its AK006 clinical program and a reduction in operating expenses following a company reorganization.

Allakos Inc. reported a net loss of $97.8 million for the first six months of 2024, alongside updates on their clinical programs and a recent restructuring.

Allakos Inc. announced its first quarter 2024 results, highlighting a significant net loss, a restructuring plan, and a focus on its lead product candidate, AK006.

Allakos Inc. filed an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.

Allakos Inc. initiates a strategic review and implements a corporate restructuring following the failure of its AK006 clinical trial, leading to a 75% workforce reduction and discontinuation of AK006 development.

Allakos Inc.'s 10-K filing details the company's focus on AK006, a strategic reorganization, and financial results for the year ended December 31, 2023.

BVF Partners L.P. and related entities report the disposition of their entire holdings in Allakos Inc. common stock due to the merger with Concentra Biosciences, LLC.

Allakos President Adam Tomasi disposed of shares and stock options following the merger agreement with Concentra Biosciences, receiving $0.33 per share.

Director Thomas Dolca reports the cancellation of stock options in Allakos Inc. due to the merger agreement with Concentra Biosciences, LLC.

Allakos CFO Radford Baird disposed of common stock and stock options following the merger agreement with Concentra Biosciences.

Director Graham Neil Murray Hamilton reports cancellation of stock options due to merger agreement.

Director Paul Edward Walker reports the disposal of Allakos Inc. shares and stock options due to the merger agreement with Concentra Biosciences, receiving $0.33 per share.

Allakos Inc. will hold its 2024 Annual Meeting of Stockholders virtually on May 24, 2024, to vote on the election of directors, ratification of the independent accounting firm, and executive compensation.

Beryl Capital Management and its affiliates have filed an amended Schedule 13G, reporting zero beneficial ownership in Allakos Inc. as of June 30, 2025.

Deep Track Capital and its affiliates have reported zero beneficial ownership in Allakos Inc. common stock, indicating a full divestment of their previous stake.